(Q40017179)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Adenosine and IFN-{alpha} synergistically increase IFN-gamma production of human NK cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

Michael P Manns

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

6

Heiner Wedemeyer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Florian Jeffe

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kerstin A Stegmann

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Felix Broelsch

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

26 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

Journal of Leukocyte Biology

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

452-461

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19095736%20AND%20SRC:MED&resulttype=core&format=json

Adenosine: an endogenous regulator of innate immunity

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine, an endogenous anti-inflammatory agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Clinical practice. Supraventricular tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine receptor signaling in the brain immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

The role and regulation of adenosine in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine deaminase deficiency: molecular basis and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Gene therapy of severe combined immunodeficiencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Expression and function of adenosine receptors in human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Pharmacology and therapeutic applications of A3 receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

A2A receptors in inflammation and injury: lessons learned from transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Positive coupling of atypical adenosine A3 receptors on human eosinophils to adenylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Activation of the A3 adenosine receptor affects cell cycle progression and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine receptors and their ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Determinants of viral clearance and persistence during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine: a physiological modulator of superoxide anion generation by human neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Activation of murine lung mast cells by the adenosine A3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine A3 receptor expression and function in eosinophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Adenosine receptors: G protein-mediated signalling and the role of accessory proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Natural killer cells in antiviral defense: function and regulation by innate cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

The role of IFN-alpha as homeostatic agent in the inflammatory response: a balance between danger and response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Noncytolytic control of viral infections by the innate and adaptive immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Immune-mediated protection from measles virus-induced central nervous system disease is noncytolytic and gamma interferon dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Borna disease virus multiplication in mouse organotypic slice cultures is site-specifically inhibited by gamma interferon but not by interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046

Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0108046